IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Teva to Buy Merck KGaA’s Generics?

1:50 PM MDT | July 26, 2007 | Chemical Week Editorial Staff

Teva Pharmaceutical Industries (Petach Tikva, Israel) is likely to be selected to acquire Merck KGaA’s generic pharmaceutical business, sources say. Merck KGaA invited offers for the business but says it has not made a final decision to divest. Aggressive bidding had pushed the price of the generics business up to €4 billion-€5 billion ($5.5 billion-$6.8 billion) by the close of a revised round of bids on April 30, sources add. The other bidders are reportedly Mylan (Canonsburg, PA), and a joint offer by private equity firms Apax Partners and Bain...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa